Former Icahn MD's Sarissa Capital Discloses 6.2% of Ariad Pharmaceuticals

According to a new filing with the SEC, Sarissa Capital Management now holds around 11.5 million shares of Ariad Pharmaceuticals, Inc.

Keep Reading →

October 29th, 2013 - Hedge Funds News